Opdivo in combination with Cabometyx shows sustained survival and response rate benefits as first-line treatment for advanced renal cell carcinoma in the Phase III CheckMate -9ER trial- BMS + Exelixis, Inc.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest